Shares of Amneal Pharmaceuticals surged 10.85% to $20.74 after the FDA approved its generic version of a long-acting injectable used to treat rare hormonal disorders and certain tumors — and the company began selling it the same day. The move adds roughly $650 million to Amneal's market capitalization, now around $6.7 billion, but the real question is how much of a nearly billion-dollar branded market Amneal can actually capture.
• Amneal Is Targeting a Drug That Still Pulls In Nearly $1 Billion a Year
U.S. annual sales of the branded version totaled $983 million for the 12 months ended July 2026, according to IQVIA data. That branded product, made by France's Ipsen, treats acromegaly (a growth hormone disorder), neuroendocrine tumors, and carcinoid syndrome — conditions that require long-term injectable therapy. For a company with $3.02 billion in 2025 revenue , even a single-digit share of this market could meaningfully move the needle.
• The Competitor's Stumble Creates a Window
Amneal is the second company to bring a generic lanreotide to the U.S. market, making three products in all. The first generic entrant, Cipla, disclosed that manufacturing has been temporarily paused due to FDA remediation at its European contract manufacturer — and the product accounts for roughly $150 million in Cipla's annual U.S. revenue with a 22% market share. That supply gap hands Amneal a rare head start. Amneal's immediate launch is supported by in-house production , meaning it doesn't face the same third-party manufacturing risk.
• The FDA Gave This Product a Special Fast Track — and That Matters
The FDA granted Competitive Generic Therapy designation, a status intended to encourage generic entry for drugs with limited competition. This signals regulators want more players here. Remarkably, the branded drug's U.S. revenue has actually grown despite Cipla's earlier entry , suggesting this market has been under-penetrated by generics — a dynamic that could let Amneal grow without immediately triggering a price war.
• Strong Momentum, But the Stock Has Already Priced In Good News Amneal shares have climbed 24.5% from their September 15 close of $16.65 in just four trading sessions. Q2 2026 revenue hit $796 million with an adjusted EBITDA of $206 million, and management raised full-year guidance for the second time. The lanreotide launch adds a durable revenue stream, but investors should watch whether Cipla restores supply and whether Ipsen cuts prices to defend share. The approval is a genuine catalyst — but at today's price, the market is already betting on execution.